Jiangsu peptide CRDMO founded in 2019 developing and manufacturing peptide active pharmaceutical ingredients - including semaglutide and teprotide - with AI-assisted discovery and green peptide synthesis technology for metabolic, anti-infective and ophthalmic indications.
No comments available.
Leave your rating & comment